Lupin's Solosec (secnidazole) Receives the US FDA's Approval for the Treatment of Trichomoniasis
Shots:
- The approval is based on a P-III clinical trial that involves assessing Solosec (2g- PO- granules) vs PBO in 64 patients with trichomoniasis
- The P-III trial demonstrated 92.2% cure rate in the modified ITT population and 94.9% in the per-protocol population- therapy was well-tolerated with no serious AEs were identified in the trial
- Additionally- the study demonstrated that ~70% of women with trichomoniasis are PCR positive for BV. Solosec (secnidazole) is the first single-dose oral prescription approved to treat both trichomoniasis & BV in the US
| Ref: Lupin | Image: PR Newswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com